SOX2 and breast carcinoma: Exposure to the adipokine visfatin may activate the SIRT1-SOX2 axis and stemness progression in breast cancer, as visfatin treatment increased sphere formation and tumor size by activating stemness-related protein expression and increasing angiogenesis, providing a malignant environment for breast cancer progression.